Calliditas Therapeutics
Sheldon Peebles has extensive work experience in the pharmaceutical industry. Starting in 2013, they worked at Biologics, Inc. as a Strategic Account Manager until 2016, and then transitioned to a Business Development role until 2017. From 2017 to 2019, they worked at TrialCard as a Program Manager, and later as an Associate Director in Market Access. In 2019, they joined GSK as a Senior Manager in Patient Access Solutions, where they worked until 2022. Currently, Sheldon is the US Market Access Operations Manager at Calliditas Therapeutics.
Sheldon Peebles attended North Carolina State University, where they earned a Bachelor of Arts degree in Communication in 2010. Prior to that, there is no information available about their education, except that they attended Virginia Episcopal School at some point.
This person is not in any offices
Calliditas Therapeutics
2 followers
Calliditas Therapeutics AB is a specialty pharmaceutical company based in Stockholm, Sweden. It is focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which Calliditas can partially or completely participate in the commercialization efforts. Calliditas is focused onthe development and commercialization of the product candidate Nefecon, a unique two step formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy (IgAN). Calliditas is running a global Phase 3 study within IgAN and aims to commercialize Nefecon in the United States.